Phase III neoadjuvant trial of pre-operative exemestane or letrozole +/- celecoxib in the treatment of ER positive postmenopausal early breast cancer.
EudraCT number 2006-000436-27
Study number BR3031
Status Actively recruiting
Opened August 2007
Expected recruitment duration 7 Years
A randomised, phase III, bifactorial clinical trial for ER positive postmenopausal early breast cancer to determine whether the addition of a COX 2 inhibitor to a 16 week treatment regimen of pre-operative exemestane or letrozole results in greater clinical response, with acceptable toxicity, than an aromatase inhibitor alone; and to determine whether exemestane provides greater objective clinical response than letrozole in the neoadjuvant setting
If you are a Health Care Professional and would like access to the site for Investigators or would like to be considered for participation in the trial please contact the NEO-EXCEL Trial Office by email email@example.com.
For general enquires about the trial please email firstname.lastname@example.org.
NEO-EXCEL is an NCRN adopted trial.